Annales pharmaceutiques francaises最新文献

{"title":"Medical cannabis: A growing opportunity for the Moroccan pharmaceutical industry","authors":"Ali Cherif Chefchaouni ,&nbsp;Ismail Bennani ,&nbsp;Soumaya El Baraka ,&nbsp;Jean Marie Ouedraogo ,&nbsp;Madiha Chentoufi Alami ,&nbsp;Fatima-Zahra Bendadi ,&nbsp;Soufiane El Marrakchi ,&nbsp;Badreddine Moukafih ,&nbsp;Younes Rahali ,&nbsp;Abdeslam El Kartouti","doi":"10.1016/j.pharma.2025.12.012","DOIUrl":"10.1016/j.pharma.2025.12.012","url":null,"abstract":"<div><div>This review highlights the pharmaceutical and galenic potential of medical cannabis and the opportunities it offers for the development of Morocco's pharmaceutical industry. Following the enactment of Law 13-21 authorizing the medical, pharmaceutical, and industrial use of cannabis, Morocco has made major progress, including the launch of its first locally produced cannabidiol-based medicine and the signing of a partnership between Mohammed VI Polytechnic University and the National Agency for the Regulation of Cannabis-Related Activities. Therapeutically, cannabinoids show promising applications in pain management, neurological, psychiatric, oncological, and ophthalmic disorders. From a formulation perspective, cannabis can be developed into various dosage forms such as oral solutions, soft capsules, sprays, transdermal patches, buccal films, medicated chewing gums, and inhalation devices. With its strong local manufacturing capacity and high generic drug penetration, Morocco's pharmaceutical ecosystem provides a favorable environment for integrating medical cannabis. Altogether, these factors position Morocco as a strategic regional hub for research, production, and pharmaceutical valorization of medical cannabis.</div></div><div><div>Cette revue met en lumière le potentiel pharmaceutique et galénique du cannabis médical et les opportunités qu’il offre pour le développement de l’industrie pharmaceutique marocaine. Après la promulgation de la loi 13-21 autorisant l’usage médical, pharmaceutique et industriel du cannabis, le Maroc a franchi des étapes majeures, notamment avec la mise sur le marché du premier médicament national à base de cannabidiol et la signature d’un accord entre l’université Mohammed VI Polytechnique et l’Agence nationale de réglementation des activités relatives au cannabis. Sur le plan thérapeutique, les cannabinoïdes présentent des applications prometteuses dans la prise en charge de la douleur, des troubles neurologiques, psychiatriques, oncologiques et ophtalmologiques. Sur le plan galénique, le cannabis peut être formulé sous diverses formes: solutions orales, capsules molles, sprays, patchs transdermiques, films buccaux, gommes médicamenteuses ou dispositifs inhalés. Le tissu industriel marocain, fort d’une capacité de fabrication locale élevée et d’une importante pénétration du générique, constitue un environnement propice à l’intégration du cannabis médical. L’ensemble de ces facteurs souligne la position stratégique du Maroc pour devenir un acteur régional dans la recherche, la production et la valorisation pharmaceutique du cannabis.</div></div>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"84 4","pages":"Pages 606-615"},"PeriodicalIF":1.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145800973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The pharmacogenetics of Tacrolimus in Algerian kidney recipients’ patients","authors":"Habiba Fetati ,&nbsp;Amani Abderahmene ,&nbsp;Fatma Boudia ,&nbsp;Lakhdar Zemour ,&nbsp;Nadjet-Fatima-Zohra Mekaouche ,&nbsp;Asmaa Memou ,&nbsp;Kada Djoudad ,&nbsp;Faiza Zerdoumi ,&nbsp;Ali Benslama ,&nbsp;Asma omezzine ,&nbsp;Houari Toumi","doi":"10.1016/j.pharma.2026.01.008","DOIUrl":"10.1016/j.pharma.2026.01.008","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;The aim of this study was to evaluate the impact of &lt;em&gt;CYP3A5*3(rs776746), CYP3A4*1B (rs2740574), CYP3A4*22 (rs35599367) and ABCB1 3435C&lt;/em&gt; &lt;em&gt;&gt;&lt;/em&gt; &lt;em&gt;T (rs1045462)&lt;/em&gt; on Tacrolimus (Tac) pharmacokinetics in the Algerian kidney transplant population.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and methods&lt;/h3&gt;&lt;div&gt;A retrospective and prospective cross-sectional study on only adult kidney recipient patients of Algerian origin who were treated with Tacrolimus regardless of the post-transplant delay. The genotyping of the four polymorphisms was performed using the Polymerase Chain Reaction (PCR) followed by Restriction Fragment Length Polymorphism (RFLP). Exposure to Tac was expressed as the ratio between the concentration and weight-adjusted dose (C0/D).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results and discussion&lt;/h3&gt;&lt;div&gt;One hundred and nine kidney recipient patients were included in the study. The genotyping revealed that 67.92% of patients were homozygous mutants for the &lt;em&gt;CYP3A5*3/*3&lt;/em&gt;, 71.29% of patients were homozygous mutants for the &lt;em&gt;CYP3A4*1B/*1B&lt;/em&gt;, 97.25% of patients were homozygous wild-type (&lt;em&gt;CYP3A4*1/*1&lt;/em&gt;) for the polymorphism &lt;em&gt;CYP3A4*22&lt;/em&gt; and 45.9% homozygous wild-type (CC) for the polymorphism &lt;em&gt;ABCB1 3435C&gt;T&lt;/em&gt;. Impact analysis of these polymorphisms on the dose and the C0/D ratio showed that only the &lt;em&gt;CYP3A5*3&lt;/em&gt; polymorphism had a significant impact on Tac dose and C0/D (&lt;em&gt;P&lt;/em&gt;˂0.001). The CYP3A5 expressors (E) patients (genotypes &lt;em&gt;*1/*1&lt;/em&gt; and &lt;em&gt;*1/*3&lt;/em&gt;) received a higher dose than non-expressors (genotype &lt;em&gt;*3/*3&lt;/em&gt;) (0.096±0.059&lt;!--&gt; &lt;!--&gt;mg/Kg vs. 0.073±0.045&lt;!--&gt; &lt;!--&gt;mg/Kg) (&lt;em&gt;P&lt;/em&gt;˂0.001) with an E/NE dose ratio of 1.31. The non-expressors (NE) patients (genotype &lt;em&gt;*3/*3&lt;/em&gt;) received Tac doses less than or equal to 0.104&lt;!--&gt; &lt;!--&gt;mg/Kg (Cuttof value) (&lt;em&gt;P&lt;/em&gt;˂0.001).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Only the &lt;em&gt;CYP3A5*3&lt;/em&gt; polymorphism influences the Tac pharmacokinetics in the Algerian kidney transplant population.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;L’objectif de cette étude était d’évaluer l’impact de &lt;em&gt;CYP3A5*3 (rs776746)&lt;/em&gt;, &lt;em&gt;CYP3A4*1B (rs2740574)&lt;/em&gt;, &lt;em&gt;CYP3A4*22 (rs35599367&lt;/em&gt;) et &lt;em&gt;ABCB1 3435C&lt;/em&gt; &lt;em&gt;&gt;&lt;/em&gt; &lt;em&gt;T (rs1045462)&lt;/em&gt; sur la pharmacocinétique du Tacrolimus (Tac) dans la population algérienne des transplantés rénaux.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Matériels et méthodes&lt;/h3&gt;&lt;div&gt;Une étude transversale rétrospective et prospective portant sur des patients adultes transplantés rénaux d’origine algérienne et traités par le Tacrolimus quel que soit le délai post-transplantation. Le génotypage des quatre polymorphismes a été réalisé par Polymerase Chain Reaction (PCR) suivi de Restriction Fragment Length Polymorphism (RFLP). L’exposition au Tac a été exprimée par le rapport entre la concentration résiduelle (C0) et la dose ajustée au poids (C0/D).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résultats et discussion&lt;/h3&gt;&lt;div&gt;Cent neuf greff","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"84 4","pages":"Pages 631-642"},"PeriodicalIF":1.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146129190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Publicité et automédication : réglementation, influence sur la consommation et risques pour le patient","authors":"Bathé-Henriette Simon ,&nbsp;Fanny Mathias ,&nbsp;Emmanuelle Tonneau Pflug","doi":"10.1016/j.pharma.2026.01.001","DOIUrl":"10.1016/j.pharma.2026.01.001","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objectifs&lt;/h3&gt;&lt;div&gt;Cette étude évalue l’influence de la publicité sur l’automédication et les connaissances des consommateurs en matière de médicaments en vente libre. Elle examine comment la publicité incite à la consommation, impacte les choix ainsi que les effets indésirables et les recours disponibles.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthodes&lt;/h3&gt;&lt;div&gt;Une enquête en ligne a été menée via un questionnaire anonyme auprès de 137 personnes à Marseille, Saint-Joseph et sur les réseaux sociaux. Le questionnaire explorait les habitudes d’automédication, les sources d’information et les connaissances des participants sur ces médicaments. Cent deux réponses ont été analysées.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résultats&lt;/h3&gt;&lt;div&gt;Près de 70 % des participants s’automédiquent, principalement pour des maux de tête, rhumes et maux de ventre. La publicité influence les choix pour 22 % d’entre eux, mais ne garantit pas la connaissance des posologies, contre-indications ou effets secondaires. Des effets indésirables liés à ces produits ont été rapportés, mais non signalés aux pharmaciens ou instances. De plus, une partie de l’échantillon n’a reçu aucune information ou conseil lors de l’achat.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;La publicité n’augmente pas la fréquence de l’automédication mais influence les choix des consommateurs. Une part importante des participants manque d’informations sur les médicaments achetés. Il est donc crucial de renforcer le rôle du pharmacien dans le conseil et l’information afin de promouvoir une automédication plus responsable et sécurisée.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;This study evaluates advertising's influence on self-medication and consumer knowledge of over-the-counter (OTC) medications. It examines how advertising encourages consumption, impacts choices, and assesses knowledge of adverse effects and reporting mechanisms.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;An anonymous online survey was conducted using a self-administered questionnaire. Out of 137 participants from Marseille, Saint-Joseph, and social media. The questionnaire explored self-medication habits, information sources, and knowledge of OTC medications. One hundred and two responses were analyzed.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Nearly 70% of participants self-medicate, mainly for headaches, colds, and stomach aches. Advertising influences choices for 22% of them but does not guarantee comprehensive knowledge of dosages, contraindications, or side effects. Furthermore, adverse effects linked to the consumption of these products were identified but not reported to pharmacists or appropriate authorities. Additionally, some participants received no information or advice upon purchase.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Advertising does not necessarily alter the frequency of self-medication but influences consumer choices towards specific products. Nevertheless, an important proportion of participants lack sufficient information about the medications they pur","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"84 4","pages":"Pages 736-748"},"PeriodicalIF":1.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146044531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact des dispositifs médicaux dans l’empreinte carbone d’une unité de chirurgie ambulatoire : état des lieux et perspectives de décarbonation","authors":"Oriane Jouhet,&nbsp;Quentin Misandeau,&nbsp;Rui Batista,&nbsp;Damien Talon","doi":"10.1016/j.pharma.2026.01.002","DOIUrl":"10.1016/j.pharma.2026.01.002","url":null,"abstract":"<div><div>Le secteur de la santé représente 8 % des émissions de gaz à effet de serre (GES) en France parmi lesquelles 30 % sont dues à l’achat de dispositifs médicaux (Tennison et al., 2021). Le groupement hospitalier souhaite évaluer l’empreinte carbone (EC) de plusieurs parcours de soin dans les unités de chirurgie ambulatoire (UCA). L’objectif du travail est d’évaluer l’empreinte carbone de l’UCA pour identifier les postes les plus émetteurs de GES. Les données d’activité de l’EC de l’UCA ont été recueillies pendant deux semaines en 2023 par une équipe pluri-professionnelle et converties en données d’émissions par des facteurs d’émission. Les émissions de GES liées aux consommations en eau, énergie, aux déplacements des patients et personnels, à la maintenance et aux achats d’équipements en 2022, à l’achat des produits de santé, à la pesée des déchets ont été mésurées. En 2022, l’UCA a émis 684 tonnes (t) CO2 pour 4884 interventions, soit 140<!--> <!-->kg eCO2 par opération. Les émissions engendrées par les achats de dispositifs médicaux à usage unique stériles (DMUUS) sont de 52 %, équipements 15 %, énergie 8 %, dispositifs médicaux re-stérilisables (DMRS) 6 %, déplacement du personnel 5 %, transport des patients 2 % et les déchets 2 %. L’achat de DMUUS est le plus émetteur de GES à l’UCA. Plusieurs actions de développement durable, déjà mises en place (sévoflurane à faible débit, tri des déchets en salle d’opération) doivent s’accompagner de nouveaux projets portant sur l’achat de DMUUS.</div></div><div><div>Healthcare represents 8% of France's greenhouse gas (GHG) emissions. Medical devices procurement contributes for 30% of this footprint. Within our hospital group, carbon footprint (CF) assessment is being extended to several care pathways in ambulatory surgery units (ASU). This study aimed to quantify the ASU CF and identify the principal emission hotspots. A multidisciplinary team performed a two-week activity-based inventory in 2023. Data were converted to CO2e using appropriate emission factors. The assessment covered water, energy, patient and staff transportation, acquisition and maintenance of equipment (allocated to 2022 activity), pharmaceutical and medical supply procurement, and waste generation quantified by weighing. For 2022, total ASU CF were estimated at 684 tCO2e for 4,884 procedures, i.e., 140<!--> <!-->kgCO2e per operation. The main contributors were single-use sterile medical devices (SUUMD) (52%), equipment (15%), energy (6%), reusable sterilizable medical devices (6%), staff transportation (5%), pharmaceuticals (3%), patient transportation (2%), and waste (2%). Single-use sterile medical devices emerged as the main driver of ASU-related emissions. Current environmental actions (e.g., low-flow sevoflurane use and improved operating-room waste segregation) should be strengthened by targeted procurement strategies for single-use sterile medical devices to achieve further reductions.</div></div>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"84 4","pages":"Pages 749-759"},"PeriodicalIF":1.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145994760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sommaire / Contents","authors":"","doi":"10.1016/S0003-4509(26)00083-0","DOIUrl":"10.1016/S0003-4509(26)00083-0","url":null,"abstract":"","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"84 4","pages":"Pages iii-iv"},"PeriodicalIF":1.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148214649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phytochemical evaluation of Glossocardia bosvallia (Linn. f.) Dc.: A dual approach against resistant Staphylococcus aureus","authors":"Soundar Rajan Kulandhaivel,&nbsp;Balasubramanian Sivaprakasam,&nbsp;Jesudass Joseph Sahayarayan","doi":"10.1016/j.pharma.2026.01.003","DOIUrl":"10.1016/j.pharma.2026.01.003","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Rising antibiotic resistance poses a serious global health threat and increasingly limits the effectiveness of conventional treatments. This challenge has intensified the search for plant-based alternatives with strong antibacterial potential. &lt;em&gt;Glossocardia bosvallia&lt;/em&gt; (Linn. f.) Dc., a medicinal plant belongs to the Asteraceae family, is traditionally valued for its therapeutic potential and is rich in bioactive phytochemicals. This study evaluated the phytochemicals composition and antibacterial activity of &lt;em&gt;G. bosvallia&lt;/em&gt; extracts against &lt;em&gt;Methicillin-resistant Staphylococcus aureus&lt;/em&gt; (MRSA) and &lt;em&gt;Methicillin-susceptible Staphylococcus aureus&lt;/em&gt; (MSSA). Phytochemical screening revealed the presence of carbohydrates, tannins, quinones, steroids, and saponins. Antibacterial assays showed that all extracts exhibited more than 70% inhibition at 100&lt;!--&gt; &lt;!--&gt;μg/mL concentration against both staphylococcal strains. GC–MS analysis identified 38 compounds in the ethanolic extract that may contribute to the observed antibacterial activity. Molecular docking demonstrated that 13Z,16Z-docosadienoic acid and quinic acid showed better binding affinities of −8.021 and −7.291&lt;!--&gt; &lt;!--&gt;kcal/mol with mecA (PBP2a) target, a key factor in resistance compared to the drug ceftobiprole with binding affinity of −4.152&lt;!--&gt; &lt;!--&gt;kcal/mol. Molecular dynamics simulation and essential dynamics confirmed the stability of these ligand–protein complexes throughout the simulation period. ADMET and DFT were further supported the drug-likeness and electronic reactivity of the lead compounds. Collectively, these findings highlight the promising potential of &lt;em&gt;G. bosvallia&lt;/em&gt; as a natural anti-staphylococcal agent.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;L’augmentation de la résistance aux antibiotiques constitue une menace majeure pour la santé mondiale et limite de plus en plus l’efficacité des traitements conventionnels. Ce défi a intensifié la recherche d’alternatives d’origine végétale présentant un fort potentiel antimicrobien. &lt;em&gt;Glossocardia bosvallia&lt;/em&gt; (Linn. f.) Dc., une plante médicinale appartenant à la famille des Asteraceae, est traditionnellement reconnue pour son potentiel thérapeutique et sa richesse en composés phytochimiques bioactifs. La présente étude a évalué la composition phytochimique et l’activité antibactérienne des extraits de &lt;em&gt;G. bosvallia&lt;/em&gt; contre &lt;em&gt;Staphylococcus aureus&lt;/em&gt; résistant à la méticilline (MRSA) et sensible à la méticilline (MSSA). Le criblage phytochimique a révélé la présence de glucides, de tanins, de quinones, de stéroïdes et de saponines. Les essais antibactériens ont montré que tous les extraits présentaient une inhibition supérieure à 70 % à une concentration de 100&lt;!--&gt; &lt;!--&gt;μg/mL contre les deux souches staphylococciques. L’analyse par GC–MS a permis d’identifier 38 composés dans l’extrait éthanolique susceptibles de contribuer à l’activité antibactérienne observée. Les études d’ amarrage molécu","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"84 4","pages":"Pages 643-661"},"PeriodicalIF":1.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146044512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of herbaceous Apiaceae plants in primary dysmenorrhea: A systematic review and meta-analysis of RCTs","authors":"Athul Thaliyil Poduval ,&nbsp;Vijaya Lekshmi Ramalekshmi ,&nbsp;Nithya Vijayan Sarangi ,&nbsp;Susdev Karippattil Murali ,&nbsp;Akash Dey ,&nbsp;Bidhan Mahajon ,&nbsp;Meenakshi Pandey ,&nbsp;Ruknuddin Galib ,&nbsp;Sanjay M. Jachak ,&nbsp;Tanuja Manoj Nesari ,&nbsp;Meena Shamrao Deogade","doi":"10.1016/j.pharma.2026.01.005","DOIUrl":"10.1016/j.pharma.2026.01.005","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Primary dysmenorrhea is a leading cause of job and school absenteeism among young females. Despite its high prevalence, contemporary medicine offers limited treatment options. Herbaceous members of the &lt;em&gt;Apiaceae&lt;/em&gt; family, such as &lt;em&gt;Pimpinella anisum&lt;/em&gt; L&lt;em&gt;., Anethum sowa&lt;/em&gt; L&lt;em&gt;.,&lt;/em&gt;&lt;em&gt;Anethum graveolens L.,&lt;/em&gt;&lt;em&gt;Cuminum cyminum&lt;/em&gt; L&lt;em&gt;., and Foeniculum vulgare&lt;/em&gt; Mill., are commonly used in traditional medicine to treat primary dysmenorrhea. Currently, there is no comprehensive assessment of their therapeutic efficacy and safety. This study assessed how effective and safe these herbs are in managing primary dysmenorrhea.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;The following electronic databases were thoroughly searched without language restriction from their inception to March 2025 by three independent reviewers: Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, AYUSH Research Portal (a database of Ayurveda and other research articles), and Digital Helpline for Ayurveda Research Articles (DHARA), SCOPUS And Google Scholar. All randomized-controlled trials that assessed the efficacy of the herbs belonging to the &lt;em&gt;Apiaceae&lt;/em&gt; family on primary dysmenorrhea were considered. The entire review was conducted in strict adherence to PRISMA guidelines. The validity and applicability of the study results were assessed with the help of risk-of-bias assessment tools.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results and discussion&lt;/h3&gt;&lt;div&gt;After the data search, screening and full-text review, 14 studies were selected for systematic review. The risk of bias assessment showed low risk in randomization and outcome measurement for studies comparing &lt;em&gt;Pimpinella anisum&lt;/em&gt;&lt;em&gt;L.&lt;/em&gt; and &lt;em&gt;Foeniculum vulgare&lt;/em&gt;Mill&lt;em&gt;.&lt;/em&gt; against placebos. However, studies using &lt;em&gt;Foeniculum vulgare&lt;/em&gt;&lt;em&gt;Mill&lt;/em&gt; and &lt;em&gt;Anethum graveolens&lt;/em&gt;L&lt;em&gt;.&lt;/em&gt;against standard treatments revealed concerns related to deviations from interventions and selective reporting, highlighting the need for improved methodological consistency. The meta-analysis included data from seven studies comparing herbaceous &lt;em&gt;Apiaceae&lt;/em&gt; family plants against standard treatments for managing primary dysmenorrhea. The pooled results against standard treatments showed a statistically significant effect with low heterogeneity. Further subgroup analysis using fennel seed and dill seed, when compared to standard treatments such as Mefenamic acid or Ibuprofen, also demonstrated a statistically significant positive outcome.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;&lt;em&gt;Apiaceae&lt;/em&gt; plants are potentially effective adjunct therapies for dysmenorrhea, though further high-quality trials are essential to confirm these findings.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;PROSPERO Registration number&lt;/h3&gt;&lt;div&gt;CRD42024538888.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Contexte&lt;/h3&gt;&lt;div&gt;La dysménorrhée primaire est l’une des principales causes d’absentéisme scolaire et professionnel chez les jeun","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"84 4","pages":"Pages 595-605"},"PeriodicalIF":1.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146138117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review exploring the translational perspective of artificial intelligence in drug discovery and formulation development","authors":"Babita Agarwal ,&nbsp;Saurabh Gaware ,&nbsp;Namdev More ,&nbsp;Rushikesh Shinde ,&nbsp;Hagalavadi Nanjappa Shivakumar ,&nbsp;Sachin Jagdale","doi":"10.1016/j.pharma.2026.01.007","DOIUrl":"10.1016/j.pharma.2026.01.007","url":null,"abstract":"&lt;div&gt;&lt;div&gt;The drug development pipeline remains extraordinarily complex, costly, and time-intensive, typically requiring 10–15&lt;!--&gt; &lt;!--&gt;years and $2–3 billion per approved drug. This review presents a translational perspective on how artificial intelligence (AI) and machine learning (ML) are renovating pharmaceutical R&amp;D across the entire value chain while maintaining rigorous safety and efficacy standards. In drug discovery, deep learning platforms enable virtual screening of billion-compounds, reducing target identification from years to months while improving hit rates by 30–50%. Preclinical development benefits from AI-powered toxicity prediction, potentially eliminating 40% of animal testing through accurate &lt;em&gt;in silico&lt;/em&gt; models. Clinical trials are optimized through digital twin technology, reducing patient cohorts by 25–30% without compromising statistical power. Post-marketing surveillance is accelerated 100-fold through AI-driven real-world evidence analysis. Across the development lifecycle, AI delivers 30–60% time savings and 25–40% cost reductions while increasing success rates through enhanced predictive capabilities. Formulation development benefits from ML algorithms that optimize drug compositions and stability, reducing trial-and-error experimentation. However, challenges persist in data quality, algorithmic bias, and regulatory acceptance of AI-derived evidence. This review provides a balanced perspective on AI's transformative potential in drug discovery and various formulation developments, along with its limitations, offering a roadmap for successful implementation in pharmaceutical R&amp;D.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;Le processus de développement des médicaments reste extrêmement complexe, coûteux et long, nécessitant généralement 10 à 15 ans et 2 à 3 milliards de dollars par médicament approuvé. Cette étude présente une perspective translationnelle sur la manière dont l’intelligence artificielle (IA) et l’apprentissage automatique (ML) révolutionnent la R&amp;D pharmaceutique tout au long de la chaîne de valeur, tout en maintenant des normes rigoureuses en matière de sécurité et d’efficacité. Dans le domaine de la découverte de médicaments, les plateformes d’apprentissage profond permettent le criblage virtuel de milliards de composés, réduisant ainsi le temps nécessaire à l’identification des cibles de plusieurs années à quelques mois, tout en améliorant les taux de réussite de 30 à 50 %. Le développement préclinique bénéficie de la prédiction de la toxicité grâce à l’IA, qui permet d’éliminer potentiellement 40 % des tests sur les animaux grâce à des modèles in silico précis. Les essais cliniques sont optimisés grâce à la technologie des jumeaux numériques, ce qui permet de réduire les cohortes de patients de 25 à 30 % sans compromettre la puissance statistique. La surveillance post-commercialisation est accélérée 100 fois grâce à l’analyse des données réelles alimentée par l’IA. Tout au long du cycle de développement","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"84 4","pages":"Pages 559-594"},"PeriodicalIF":1.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146138144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vie de l’Académie – 2e semestre 2025","authors":"","doi":"10.1016/j.pharma.2025.12.010","DOIUrl":"10.1016/j.pharma.2025.12.010","url":null,"abstract":"","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"84 2","pages":"Pages 326-338"},"PeriodicalIF":1.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147409420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"L’éco-prescription, une nouvelle compétence majeure pour les professionnels de santé","authors":"Frédéric Bounoure ,&nbsp;Salomé Dupray ,&nbsp;Julien Wils ,&nbsp;Sébastien Taillemite ,&nbsp;Matthias Brunn ,&nbsp;Charlotte Siefridt ,&nbsp;Noémie Le Clech ,&nbsp;Mathilde Réveillon-Istin ,&nbsp;Mohamed Skiba ,&nbsp;Céline Bouglé ,&nbsp;Malika Lahiani-Skiba","doi":"10.1016/j.pharma.2025.10.003","DOIUrl":"10.1016/j.pharma.2025.10.003","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Les émissions de gaz à effet de serre (GES) du secteur de la santé représentent environ 8 % des émissions françaises. Les médicaments constituent le premier poste d’émission avec 9,1Mt de CO&lt;sub&gt;2&lt;/sub&gt;eq annuels. L’objectif de ce travail est de proposer à qualité des soins similaire des principes d’éco-prescription des médicaments pour diminuer l’empreinte carbone des prescriptions. Une étude des recommandations actuelles couplée à une analyse bibliographique a permis d’identifier les recommandations les plus pertinentes. Elle a été complétée par une analyse de la base de données Ecovamed® sur l’empreinte carbone des médicaments. Celle-ci a porté sur neuf classes de médicaments. L’unité fonctionnelle utilisée a été la Dose Définie Journalière (DDJ) normalisée sur un conditionnement mensuel. Cinq principes d’éco-prescription ont été définis : (1) privilégier les formes orales sèches par rapport aux formes buvables ou parentérales (émissions de GES divisées d’un facteur 2 à 130), (2) limiter la prescription d’inhalateurs pressurisés (émissions divisées par 10 à 20 si utilisation d‘un inhalateur poudre), (3) privilégier au sein d’une même classe thérapeutique les molécules aux DDJ les plus faibles (réduction de 30 % par rapport à la moyenne de la classe thérapeutique), (4) privilégier l’utilisation des spécialités combinées (réduction de 29 % vs les 2 spécialités) et (5) privilégier les schémas posologiques avec un minimum de doses à administrer (réduction de 37 %). Leur mise en œuvre est simple avec un impact majeur et sans surcoût. Cependant elle devrait s’inscrire dans une démarche plus globale centrée sur le bon usage et la pertinence des soins. L’éco-prescription constitue un changement majeur dans nos pratiques pharmaceutiques et médicales.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;Healthcare-related carbon emissions account for about 8% of national emissions. Drugs are the primary source of emissions, contributing 9.1 Mt of CO&lt;sub&gt;2&lt;/sub&gt; per year. The objective of this work is to better define the eco-prescription of medicines and the means of implementation to favor therapeutic strategies that are more environmentally virtuous while maintaining the quality of care. The most relevant recommendations were identified by a study of the current recommendations coupled with a bibliographical analysis. It was supplemented by an analysis of the Ecovamed® database on the carbon footprint of medicines. This study covered nine classes of common drugs. The functional unit used was the standardized Daily Defined Dose (DDD) on a monthly package. Five principles of eco-prescription have been proposed: Give preference to dry oral forms (greenhouse gas emissions divided by 2 to 130), Avoid prescribing pressurized inhalers (emissions divided by 10 to 20 when using powder inhalers), Give preference within the same therapeutic class to drugs with the lowest daily doses of active ingredient (reduction of 30% vs. the average of therapeutic class), give preference to drugs","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"84 2","pages":"Pages 285-294"},"PeriodicalIF":1.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145277072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}